Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Pramiracetam and PRL-8-53 — mechanism, side effects, legal status, and pricing.
Pramiracetam is a non-peptide synthetic racetam-class nootropic (2-oxopyrrolidone/pyrrolidinone acetamide derivative) with CAS 68497-62-1 and molecular formula C14H27N3O2. It was previously approved and marketed in Italy and some Eastern European countries under brand names Pramistar, Neupramir, and Remen for memory/attention deficits in aging-associated dementias; Italian authorization was revoked in 2020 at manufacturer request. It is not FDA-approved in the United States, where it is sold only as an unapproved gray-market research chemical. The related racetam phenylpiracetam is explicitly listed on the WADA Prohibited List as an S6 stimulant; pramiracetam itself is not explicitly named, leaving its status under WADA's 'similar structure/effect' catch-all unresolved.
PRL-8-53 is a non-peptide small-molecule aminoalkyl benzoic acid ester (methyl benzoate derivative), supplied as the hydrochloride salt. Originally characterized in 1974 animal studies as a spasmolytic and CNS-active agent, it has never been approved by any regulatory agency and is sold only as a research chemical. Exactly one published human trial exists—a 1978 double-blind study on verbal learning and retention—with no independent replication or modern safety data.
Pramiracetam
PRL-8-53
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Pramiracetam
No pricing data yet.
Check Pramiracetam prices →PRL-8-53
COA corpus from Disclosed Labs — independently tested batches only.
Pramiracetam
2
COAs
99.9%
Avg purity
2
Labs
PRL-8-53
3
COAs
96.8%
Avg purity
2
Labs
Human data consist of a handful of small older trials (1985–1996): healthy-volunteer pharmacokinetic studies, a scopolamine-induced-amnesia challenge study, a placebo-controlled trial in young males with head-injury/anoxia-related memory deficits (400 mg TID improved delayed recall), and a small dose-finding trial in Alzheimer's disease that found no convincing benefit at doses up to 4,000 mg. A scopolamine-challenge study (600 mg BID × 10 days) showed partial mitigation of induced amnesia in healthy young and older male volunteers. No modern (post-2000) randomized controlled trials were located. Preclinical findings: in rats, 7.5 and 15 mg/kg/day × 7 weeks significantly improved reference (long-term) memory on a 16-arm radial maze but did not affect working memory; 300 mg/kg i.p. increased cortical nitric oxide synthase activity ~20% (synergistic ~40% increase with lithium pretreatment); moderate protection against hypobaric-hypoxia-induced deficits in immature rats.
Exactly one published human study was located: a 1978 double-blind trial (Hansl & Mead, <em>Psychopharmacology</em>, PMID 418433) using the serial anticipation method to test oral PRL-8-53 on verbal learning acquisition and retention, with follow-up on visual reaction time and motor control; the study reported statistically significant retention improvement (most P<0.01) and no significant reaction-time or motor effects, but sample size and exact dose are not stated in the available abstract. No further human trials were found, and no ClinicalTrials.gov entries exist. Preclinical work is limited to the 1974 Hansl paper (PMID 4824605) in dogs and rats, indexed for avoidance learning, conditioning, memory, and pharmacological interaction with apomorphine and methamphetamine, though full quantitative findings could not be verified because no abstract text is available.
Pramiracetam and PRL-8-53 are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs